Free Newsletter
Lilly strengthens Zyprexa warnings
Eli Lilly is owning up to Zyprexa's ills in new warnings added to the medicine's label. The schizophrenia drug will now be tagged with weight gain, high blood sugar high cholesterol, and other metabolic problems.
It's the first time Zyprexa's label has acknowledged that it causes high blood sugar more readily than other atypical antipsychotics. In fact, Lilly has argued against it, saying that the difference wasn't proven. The label also admits that weight gain may continue for as long as two years, rather than plateauing in a few months as previously stated.
Though Zyprexa has steadily lost market share since 2004 because of side effects, it still delivered $2.3 billion in worldwide sales the first half of this year.
- see Lilly's release
- read the article from the New York Times
Related Articles:
Lilly CEO: Use IT to boost drug safety. Report
Eli Lilly pairs with GE to study cancer drugs. Report
Lilly developing biotech drugs the old-fashioned way. Report
Lilly accused of promoting off-label Zyprexa use. Report
NYT accuses Lilly of hiding safety problems. Report
Comments
Post new comment
Paid Research Reports
- The Top 10 Biosimilar Players: Positioning, performance and SWOT analyses
- New Approaches to Pharma R&D: Evolving strategies to rejuvenate R&D efficiency
- Stakeholder Opinions: Vaccine antigen delivery technologies - Molecular systems to open new markets
- The Top 10 Contract Research Organizations
- Stakeholder Opinions: Vaccine administration technologies - Beyond needles
- Future Pharmaceutical Industry Trends: Long-term opportunities tempered by short-term challenges





Click here to get the FiercePharma email newsletter for FREE!
Be the first to comment